Table 1. The characteristics of included RCTs.
| First author | Type of COVID-19 | Sample size (M/F) | Age (yrs) | Intervention | Control | Duration | Outcome measures |
|---|---|---|---|---|---|---|---|
| Duan C [15] | mild | T:82(39/43) C:41(23/18) | T:51.99±13.88 C:50.29±13.17 | Jinhua Qinggan granule and conventional therapy | Conventional therapy | 5 days | ⑤+⑦ |
| Fu [16] | mild/ moderate | T:32(17/15) C:33(19/14) | T:43.26±7.15 C:43.68±6.45 | Toujie Quwen granule and conventional therapy | Conventional therapy | 10 days | ①+②+③+⑤+⑥+⑦ |
| Fu XX [17] | moderate | T:37(19/18) C:36(19/17) | T:45.26±7.25 C:44.68±7.45 | Toujie Quwen granule and conventional therapy | Conventional therapy | 15 days | ②+③+⑤+⑥+⑦ |
| Hu F [18] | moderate | T:100(49/51) C:100(55/45) | T:47.00±14.06 C:49.28±11.14 | Jinyinhua oral liquid and conventional therapy | Conventional therapy | 10 days | ①+③+④+⑦ |
| Hu K [19] | mild/ moderate | T:142(79/63) C:142(71/71) | T:50.4±15.2 C:51.8±14.8 | Lianhua Qingwen capsule and conventional therapy | Conventional therapy | 14 days | ①+②+③+④+⑤+⑦ |
| Qiu M [20] | moderate | T:25(13/12) C:25(14/11) | T:53.35±18.35 C:51.32±14.62 | Maxing Xuanfei Jiedu Decoction and conventional therapy | Conventional therapy | 10 days | ①+③+⑤ |
| Sun HM [21] | mild/ moderate | T:32(17/15) C:25(11/14) | T:45.4±14.10 C:42.0±11.70 | Lianhua Qingke granule and conventional therapy | Conventional therapy | 14days | ①+③+⑤ |
| Yang MB [22] | moderate | T:26(16/10) C:23(9/14) | T:50.35±13.37 C:47.17±16.57 | Reyanning mixture and conventional therapy | Conventional therapy | 7 days | ③+④+⑤+⑥+⑦ |
| Yu P [23] | mild/ moderate | T:147(82/65) C:148(89/59) | T:48.27±9.56 C:47.25±8.67 | Lianhua Qingwen granule and conventional therapy | Conventional therapy | 7 days | ①+②+③+⑤+⑥+⑦ |
| Zhang CT [24] | moderate | T:22(9/13) C:23(10/13) | T:53.7±3.5 C: 55.6±4.2 | Jiawei Dayuan Decoction and conventional therapy | Conventional therapy | 7 days | ①+⑤+⑥+⑦ |
| Zhang YL [25] | moderate | T:80(50/30) C:40(23/17) | T:53.4±13.70 C:52.0±14.10 | Jinyinhua oral liquid and conventional therapy | Conventional therapy | 10 days | ③+⑤+⑦ |
| Zhou WM [26] | moderate | T:52(32/20) C:52(28/24) | T:52.47±10.99 C:51.11±9.87 | diammonium glycyrrhizinate and conventional therapy | Conventional therapy | 14 days | ②+⑥+⑦ |
①: Lung CT; ②: Clinical cure rate; ③: Rate of conversion to severe cases; ④: Virus nucleic acid testing; ⑤: Clinical symptoms; ⑥: Inflammatory biomarkers; ⑦: Adverse events.